Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer.
Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer.
复制标题
DOI：
10.1016/j.hemonc.2014.11.003
复制
发表时间：
2015-03-01
期刊：
影响因子：
--
通讯作者：
Swiha, M M
中科院分区：
文献类型：
--
作者：
Alagizy, H A;Shehata, M A;Swiha, M M
目得：对三阴性乳腺癌的高度关注并不奇怪，因为这类患者既不受益于激素治疗，也不受益于抗HER 2治疗。节拍化疗和其他抗血管生成药物阻断血管生成可能会改善这组患者的预后。本研究的目的是评估的耐受性和疗效节拍卡培他滨作为扩展的辅助治疗妇女与三阴性breastcancer.METHODS：这是一个前瞻性的II期研究，包括41例诊断为三阴性乳腺癌和谁是辅助化疗。他们接受卡培他滨500 mg PO，每日2次，连续6个月后完成6个周期的辅助FEC 100 ±术后放疗。中位年龄为50岁，范围为27 - 67岁。治疗耐受性良好。不良反应为13名患者（31.7%）出现1级掌跖红斑感觉迟钝; 5名患者（12.2%）出现1级腹泻; 2名患者（4.9%）出现1级呕吐。估计中位随访时间为34个月。估计平均无病生存期（DFS）为42.4个月（95%CI，39.02-45.79），而未达到中位DFS。估计的平均总生存期为44.34个月（95%CI 41.9-46.9）。结论：扩展辅助节拍卡培他滨是耐受性良好的患者依从性。这些结果需要在对照组、更大样本以及更长随访的研究中进行比较。
PURPOSE: High interest in triple-negative breast cancers is not surprising as this category of patients benefits neither from hormonal therapies nor from anti HER2 treatments. Blockade of angiogenesis by metronomic chemotherapy as well as other antiangiogenics might improve outcomes in this group of patients. This study aims to evaluate the tolerability and efficacy of metronomic capecitabine as extended adjuvant treatment for women with triple-negative breast cancer.METHODS: This is a prospective phase II study that included 41 patients diagnosed with triple-negative breast cancer and who were indicated for adjuvant chemotherapy. They received capecitabine 500mg PO twice daily and continuously for six months after finishing six cycles of adjuvant FEC100±postoperative radiotherapy.RESULTS: Forty-one patients were enrolled in this study between June 2010 and December 2013. Median age was 50years ranging from 27 to 67years. Treatment was well tolerated. Adverse effects were grade 1 palmar-plantar erythrodysesthesia in 13 patients (31.7%); grade 1 diarrhea in five patients (12.2%); and grade 1 vomiting in two patients (4.9%). Estimated median follow-up duration was 34 months. Estimated mean disease-free survival (DFS) was 42.4months (95% CI, 39.02-45.79), while median DFS was not reached. Estimated mean overall survival was 44.34months (95% CI 41.9-46.9).CONCLUSION: Extended adjuvant metronomic capecitabine is well tolerated with patient compliance. These results need to be compared in a study with control arm, larger sample, as well as longer follow-up.